clemastine (TAVIST) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Clemastine is an antihistamine with anticholinergic (drying) and sedative side effects. Clemastine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is used for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.   NCATS

Chemistry

  • SMILES: CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
  • InChIKey: YNNUSGIPVFPVBX-NHCUHLMSSA-N
  • Mol. Mass: 343.9
  • ALogP: 5.1
  • ChEMBL Molecules:
    clemastine  
    clemastine fumarate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.5969
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( acetaminophen (tylenol), clemastine (TAVIST), pseudoephedrine (Benylin) )

Alternative names

(+)-(2r)-2-(2-(((r)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine | (+)-(2r)-2-[2-[[(r)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine | clemastin | clemastina | clemastine | clemastine fumarate | clemastinum | hs-592 | meclastin | meclastine | tavegil | tavist | tavist-1

Organizations (21)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (4)


 

Common Cold

Rhinitis, Allergic (approved 1992)

Rhinitis, Allergic, Seasonal

Urticaria (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Angioedema (Phase 3)

Chronic Urticaria (Phase 2)

Demyelinating Diseases (Phase 1/Phase 2)

Dermatitis (Phase 3)

Healthy Volunteers (Phase 1)

Hypersensitivity (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 1/Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Ocular Motility Disorders (Phase 3)

Optic Neuritis (Phase 2)

Williams Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue